Financial Performance - The company reported a solid fourth quarter with a 3% organic revenue growth and a 4% reported revenue increase year over year [6][28] - Adjusted EPS for Q4 was $0.53 compared to $0.49 in the prior year, while GAAP EPS was a loss of $0.11 compared to a positive $0.25 in the prior year [28] - Total company adjusted gross margin was 70.1% in Q4, down from 71.1% the previous year, primarily due to unfavorable product mix [29][30] - Adjusted operating margin for Q4 was 32%, down 150 basis points compared to the prior year [30] Business Segment Performance - The Protein Sciences segment reported sales of $226.5 million, with organic revenue growth of 4% for the quarter [33] - The Diagnostics and Spatial Biology segment had Q4 sales of $89.7 million, with both reported and organic growth decreasing by 1% compared to the same period last year [34] - The company divested its Exosome Diagnostics business, which had a revenue of $25.9 million in fiscal 2025, impacting the corporate adjusted operating margin by 200 basis points [35] Market Performance - Biopharma end market delivered high single-digit growth for both Q4 and the full fiscal year, driven by large pharmaceutical customers [13][29] - Academic revenue declined low single digits in Q4 but increased low single digits for the full fiscal year, with U.S. institutions contributing approximately 12% [17][29] - China experienced low double-digit growth in Q4, attributed to demand improvement ahead of tariff uncertainties [18][29] Company Strategy and Industry Competition - The company announced the divestiture of its exosome diagnostics business to focus on core growth pillars and improve operating margins [10][11] - The company aims to balance strategic investments for future growth with productivity initiatives to enhance profitability [40] - The company is committed to M&A as a priority for capital allocation, focusing on high-margin, high-volume products [61] Management Commentary on Operating Environment and Future Outlook - Management expressed concerns about uncertainties in the pharmaceutical landscape due to potential tariffs and drug pricing models [12][37] - The company anticipates low single-digit organic growth until uncertainties around NIH funding and pharmaceutical tariffs are resolved [38][39] - Management remains optimistic about long-term growth drivers, including an aging population and increasing demand for life sciences innovations [39] Other Important Information - The company generated $98.2 million in cash from operations in Q4 and returned $12.4 million in dividends and $100.1 million through stock buybacks [31] - The company finished Q4 with $162.2 million in cash and total leverage well below one times EBITDA [32] Q&A Session Summary Question: Guidance for fiscal 2026 growth - Management clarified that low single-digit growth is expected until there is more certainty around various administration policies [43] Question: Performance of instrumentation in large pharma - Management noted strong growth in instrumentation for large pharma, particularly with the new LEO system tailored for high throughput [45][46] Question: Commitment to market growth above peers - Management acknowledged that in a turbulent environment, outperforming by 500 basis points is challenging but remains hopeful for clarity around key issues [49] Question: Drivers of margin expansion - Management indicated that margin expansion is driven by the divestiture of Exosome Diagnostics and ongoing productivity initiatives [50][70] Question: NIH funding and academic customer behavior - Management observed that academic institutions are behaving conservatively, holding back on spending in anticipation of funding outcomes [59][95] Question: Growth in China - Management confirmed that growth in China was influenced by funding releases and anticipation of tariff impacts, but expects stable growth moving forward [67][92]

Financial Data and Key Metrics Changes - The company reported adjusted EPS of $0.53 for Q4, up from $0.49 in the prior year, while GAAP EPS was a loss of $0.11 compared to a profit of $0.25 in the previous year [28] - Q4 revenue reached $317 million, reflecting a 3% organic growth year-over-year and a 4% reported growth [28] - Total adjusted gross margin was 70.1% in Q4, down from 71.1% the previous year, primarily due to an unfavorable product mix [29] Business Line Data and Key Metrics Changes - The Protein Sciences segment reported sales of $226.5 million, with organic revenue growth of 4% for the quarter, driven by strong performances in cell therapy and protein analytical tools [32] - The Diagnostics and Spatial Biology segment saw Q4 sales of $89.7 million, with both reported and organic growth decreasing by 1% compared to the same period last year [32] - The divestiture of the Exosome Diagnostics business is expected to improve the operating margin in the Diagnostics and Spatial Biology segment [35] Market Data and Key Metrics Changes - Biopharma end market delivered high single-digit growth for both Q4 and the full fiscal year, driven by large pharmaceutical customers [13] - Academic revenue represented approximately 21% of total business, with U.S. institutions contributing roughly 12%, and the exposure to NIH funding was reassessed to be less than one-third [14][15] - China experienced low double-digit growth in Q4, attributed to demand improvement ahead of anticipated tariff impacts [17] Company Strategy and Development Direction - The company announced the divestiture of its exosome diagnostics business to focus on core growth pillars and improve profitability [10][11] - Strategic investments will be redirected towards advancing automated proteomic analysis and spatial biology platforms, as well as expanding applications in cell therapy [39] - The company aims to achieve adjusted operating margin expansion of approximately 100 basis points in fiscal year 2026 compared to fiscal year 2025 [40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating a dynamic market environment, with expectations of low single-digit organic growth until uncertainties around NIH funding and pharmaceutical tariffs are resolved [38] - The company remains optimistic about long-term growth drivers, including an aging global population and increasing demand for life sciences innovations [39] - Management noted that the current cautious purchasing behavior among U.S. academic customers is expected to persist until funding uncertainties are clarified [92] Other Important Information - The company generated $98.2 million in cash from operations in Q4 and returned $12.4 million in dividends and $100.1 million through stock buybacks [31] - The balance sheet ended Q4 with $162.2 million in cash and total leverage well below one times EBITDA [31] Q&A Session Summary Question: Clarification on growth outlook for fiscal year 2026 - Management clarified that low single-digit growth is expected until there is more certainty around various administration policies affecting academic funding and pharmaceutical tariffs [42] Question: Performance of instrumentation in large pharma - Management noted strong growth in instrumentation for large pharma, particularly the LEO system tailored for high throughput applications [44] Question: Commitment to market plus 500 basis points growth - Management acknowledged that in a turbulent environment, achieving that growth may be challenging, but they remain confident in their differentiation from peers [48] Question: Drivers of margin expansion - Margin expansion is expected to be driven by the divestiture of Exosome Diagnostics, which was a headwind to margins in fiscal year 2025 [49] Question: NIH funding sources for academic customers - Management indicated that approximately 50-55% of academic funding comes from federal sources, with NIH accounting for about half of that [51] Question: Outlook for China market - Management highlighted that growth in China was driven by funding releases and anticipation of tariff impacts, with expectations for modest growth moving forward [66] Question: Visibility on biotech funding - Management is monitoring biotech funding closely, noting recent signs of improvement but acknowledging that it remains significantly down year-over-year [93]

Company Performance - Techne (TECH) reported quarterly earnings of $0.53 per share, exceeding the Zacks Consensus Estimate of $0.50 per share, and showing an increase from $0.49 per share a year ago, resulting in an earnings surprise of +6.00% [1] - The company achieved revenues of $316.96 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.48% and up from $306.1 million year-over-year [2] - Over the last four quarters, Techne has consistently surpassed consensus EPS and revenue estimates [2] Stock Outlook - Despite the positive earnings report, Techne shares have declined approximately 24.1% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is $0.44 on revenues of $295.53 million, and for the current fiscal year, it is $2.07 on revenues of $1.28 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Techne belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - The performance of Techne's stock may be influenced by the overall outlook of the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

[Executive Summary & Highlights](index=1&type=section&id=Executive%20Summary%20%26%20Highlights) [CEO Commentary](index=1&type=section&id=CEO%20Commentary) Bio-Techne CEO Kim Kelderman reported robust Q4 FY2025 performance, driven by cell therapy and protein analysis, with a strategic divestiture of Exosome Diagnostics to enhance profitability - The company demonstrated **robust performance** in Q4 FY2025, meeting expectations, particularly with strong growth in **cell therapy and protein analysis instrument** pillars, supported by a resilient pharmaceutical market[6](index=6&type=chunk) - The company announced the divestiture of its Exosome Diagnostics business, including the ExoDx Prostate Test (EPI), to immediately **enhance profitability** and increase focus on **high-growth, non-CLIA product lines**[6](index=6&type=chunk)[8](index=8&type=chunk) [Key Financial & Strategic Highlights](index=1&type=section&id=Key%20Financial%20%26%20Strategic%20Highlights) Q4 FY2025 organic revenue grew 3% to **$317 million**, with full-year organic revenue up 5% to **$1.2 billion**, while adjusted diluted EPS increased **8.2%** to **$0.53**, supported by strong Protein Sciences and strategic divestitures Key Financial Metrics for Q4 and Full Year Fiscal 2025 | Metric | Q4 FY2025 | Q4 FY2024 | Y-o-Y Change | Full Year FY2025 | Full Year FY2024 | Y-o-Y Change | | :------------------- | :----------------- | :----------------- | :--------- | :------------- | :------------- | :--------- | | Organic Revenue | $317.0 Million | - | +3% | $1.2 Billion | - | +5% | | Reported Revenue | $317.0 Million | - | +4% | $1.2 Billion | - | +5% | | GAAP EPS | $(0.11) | $0.25 | -144% | $0.46 | $1.05 | -56.2% | | Adjusted EPS | $0.53 | $0.49 | +8.2% | $1.92 | $1.77 | +8.5% | | Protein Sciences Organic Growth | +4% | - | - | +5% | - | - | [Financial Performance - Fourth Quarter Fiscal 2025](index=2&type=section&id=Financial%20Performance%20-%20Fourth%20Quarter%20Fiscal%202025) [Revenue Analysis (Q4)](index=2&type=section&id=Revenue%20Analysis%20(Q4)) Net sales for Q4 FY2025 increased 4% to **$317 million**, with organic revenue growing 3%, positively impacted by foreign exchange rates and negatively by non-recurring revenue from businesses held for sale Q4 FY2025 Revenue Overview | Metric | Amount (Million USD) | Y-o-Y Change | | :----- | :------------------- | :----------- | | Net Sales | $317.0 | +4% | | Organic Revenue | - | +3% | | Foreign Exchange Impact | - | +2% (Favorable) | | Businesses Held for Sale Impact | - | -1% (Unfavorable) | [GAAP Earnings (Q4)](index=2&type=section&id=GAAP%20Earnings%20(Q4)) Q4 FY2025 GAAP diluted EPS was **$(0.11)**, a 144% decrease from **$0.25** in the prior year, primarily due to an impairment charge related to the Exosome Diagnostics business Q4 FY2025 GAAP Earnings | Metric | Q4 FY2025 | Q4 FY2024 | Y-o-Y Change | | :----------------- | :----------------- | :----------------- | :--------- | | GAAP EPS | $(0.11) | $0.25 | -144% | | GAAP Operating Income | $(23.9) Million USD | $45.8 Million USD | -152% | | GAAP Operating Margin | (7.5)% | 15.0% | -22.5 pp | | Impacting Factors | Exosome Diagnostics business impairment | - | - | [Non-GAAP Earnings (Q4)](index=2&type=section&id=Non-GAAP%20Earnings%20(Q4)) Adjusted diluted EPS for Q4 FY2025 increased to **$0.53** from **$0.49** in the prior year, while adjusted operating margin decreased to **32.0%** from **33.5%**, mainly due to an unfavorable product mix in the Diagnostics and Spatial Biology segment Q4 FY2025 Non-GAAP Earnings | Metric | Q4 FY2025 | Q4 FY2024 | Y-o-Y Change | | :----------------- | :----------------- | :----------------- | :--------- | | Adjusted EPS | $0.53 | $0.49 | +8.2% | | Adjusted Operating Income | $101.3 Million USD | $101.8 Million USD | -0.5% | | Adjusted Operating Margin | 32.0% | 33.5% | -1.5 pp | | Impacting Factors | Unfavorable product mix (Diagnostics and Spatial Biology segment) | - | - | [Financial Performance - Full Year Fiscal 2025](index=2&type=section&id=Financial%20Performance%20-%20Full%20Year%20Fiscal%202025) [Revenue Analysis (Full Year)](index=2&type=section&id=Revenue%20Analysis%20(Full%20Year)) Full-year FY2025 net sales increased 5% to **$1.2 billion**, with organic revenue also growing 5%, and no significant impact from foreign exchange rates or businesses held for sale Full Year FY2025 Revenue Overview | Metric | Amount (Billion USD) | Y-o-Y Change | | :----- | :------------------- | :----------- | | Net Sales | $1.2 | +5% | | Organic Revenue | - | +5% | | Foreign Exchange Impact | No significant impact | - | | Businesses Held for Sale Impact | No significant impact | - | [GAAP Earnings (Full Year)](index=2&type=section&id=GAAP%20Earnings%20(Full%20Year)) Full-year FY2025 GAAP diluted EPS was **$0.46**, a 56.2% decrease from **$1.05** in the prior year, primarily impacted by asset impairment, restructuring costs, and a non-recurring arbitration award Full Year FY2025 GAAP Earnings | Metric | Full Year FY2025 | Full Year FY2024 | Y-o-Y Change | | :----------------- | :------------- | :------------- | :--------- | | GAAP EPS | $0.46 | $1.05 | -56.2% | | GAAP Operating Income | $102.3 Million USD | $206.7 Million USD | -51% | | GAAP Operating Margin | 8.4% | 17.8% | -9.4 pp | | Impacting Factors | Asset impairment held for sale, restructuring costs, non-recurring arbitration award | - | - | [Non-GAAP Earnings (Full Year)](index=2&type=section&id=Non-GAAP%20Earnings%20(Full%20Year)) Full-year FY2025 adjusted diluted EPS increased to **$1.92** from **$1.77** in the prior year, with adjusted operating margin slightly decreasing to **31.6%** due to the reinstatement of incentive compensation accruals and an unfavorable product mix Full Year FY2025 Non-GAAP Earnings | Metric | Full Year FY2025 | Full Year FY2024 | Y-o-Y Change | | :----------------- | :------------- | :------------- | :--------- | | Adjusted EPS | $1.92 | $1.77 | +8.5% | | Adjusted Operating Income | $383.6 Million USD | $370.2 Million USD | +4% | | Adjusted Operating Margin | 31.6% | 32.1% | -0.5 pp | | Impacting Factors | Reinstatement of incentive compensation accruals, unfavorable product mix | - | - | [Segment Results](index=2&type=section&id=Segment%20Results) [Protein Sciences Segment](index=2&type=section&id=Protein%20Sciences%20Segment) The Protein Sciences segment reported a 6% increase in net sales to **$226.5 million** in Q4 FY2025, with organic revenue growth of 4% and an improved operating margin of **43.6%**, driven by favorable volume leverage and ongoing profitability initiatives Protein Sciences Segment Performance Overview | Metric | Q4 FY2025 | Q4 FY2024 | Y-o-Y Change | Full Year FY2025 | Full Year FY2024 | Y-o-Y Change | | :----------------- | :----------------- | :----------------- | :--------- | :------------- | :------------- | :--------- | | Net Sales | $226.5 Million USD | $214.0 Million USD | +6% | $870.2 Million USD | $830.9 Million USD | +5% | | Organic Revenue Growth | +4% | - | - | +5% | - | - | | Operating Margin | 43.6% | 43.0% | +0.6 pp | 42.6% | 42.7% | -0.1 pp | | Impacting Factors (Q4) | Favorable volume leverage, profitability initiatives | - | - | - | - | - | [Diagnostics and Spatial Biology Segment](index=4&type=section&id=Diagnostics%20and%20Spatial%20Biology%20Segment) The Diagnostics and Spatial Biology segment experienced a 1% decrease in net sales to **$89.7 million** in Q4 FY2025, with organic revenue also down 1%, and an operating margin decline to **6.0%** primarily due to an unfavorable product mix and an **$83.1 million** impairment charge for Exosome Diagnostics Diagnostics and Spatial Biology Segment Performance Overview | Metric | Q4 FY2025 | Q4 FY2024 | Y-o-Y Change | Full Year FY2025 | Full Year FY2024 | Y-o-Y Change | | :----------------- | :----------------- | :----------------- | :--------- | :------------- | :------------- | :--------- | | Net Sales | $89.7 Million USD | $90.7 Million USD | -1% | $346.3 Million USD | $326.4 Million USD | +6% | | Organic Revenue Growth | -1% | - | - | +6% | - | - | | Operating Margin | 6.0% | 12.5% | -6.5 pp | 6.2% | 7.5% | -1.3 pp | | Impacting Factors (Q4) | Unfavorable product mix, Exosome Diagnostics business impairment $83.1 Million USD | - | - | - | - | - | [Non-GAAP Financial Measures](index=5&type=section&id=Non-GAAP%20Financial%20Measures) [Definition and Rationale](index=5&type=section&id=Definition%20and%20Rationale) The company provides non-GAAP financial measures to assess operational performance and inform internal decisions, including incentive compensation, by excluding non-recurring or non-core items for transparent and comparable period results - Non-GAAP metrics are used for performance evaluation and internal decision-making, including incentive compensation, aiming to provide more transparent and comparable period results[21](index=21&type=chunk) - Organic revenue excludes acquisitions, foreign exchange impacts, businesses held for sale, and certain equity method investee revenues to provide more comparable revenue results[22](index=22&type=chunk) - Adjusted gross margin, operating margin, EBITDA, and net earnings exclude non-recurring or non-core items such as stock-based compensation, acquisition inventory step-up, intangible asset amortization, restructuring costs, asset impairment, acquisition-related expenses, and certain litigation costs[23](index=23&type=chunk)[24](index=24&type=chunk)[25](index=25&type=chunk) [Reconciliation of Adjusted Gross Margin](index=10&type=section&id=Reconciliation%20of%20Adjusted%20Gross%20Margin) Q4 FY2025 GAAP gross margin was **62.7%**, while adjusted gross margin was **70.0%**, with full-year GAAP gross margin at **64.8%** and adjusted gross margin at **70.4%**, primarily adjusted for acquisition inventory step-up, intangible asset amortization, stock-based compensation, and restructuring costs Reconciliation of Adjusted Gross Margin | Metric | Q4 FY2025 | Q4 FY2024 | Full Year FY2025 | Full Year FY2024 | | :--------------------------------- | :----------------- | :----------------- | :------------- | :------------- | | GAAP Gross Margin | 62.7% | 66.4% | 64.8% | 66.4% | | Adjusted Gross Margin | 70.0% | 71.1% | 70.4% | 71.0% | | Key Adjustments (Q4) | Acquisition inventory step-up $0.2M, Intangible asset amortization $10.6M, Stock-based compensation $0.3M, Restructuring costs $12.1M | - | - | - | [Reconciliation of Adjusted Operating Margin](index=10&type=section&id=Reconciliation%20of%20Adjusted%20Operating%20Margin) Q4 FY2025 GAAP operating margin was **(7.5)%**, while adjusted operating margin was **32.0%**, with full-year GAAP operating margin at **8.4%** and adjusted operating margin at **31.6%**, primarily adjusted for intangible asset amortization, stock-based compensation, restructuring costs, and asset impairment held for sale Reconciliation of Adjusted Operating Margin | Metric | Q4 FY2025 | Q4 FY2024 | Full Year FY2025 | Full Year FY2024 | | :--------------------------------- | :----------------- | :----------------- | :------------- | :------------- | | GAAP Operating Margin | (7.5)% | 15.0% | 8.4% | 17.8% | | Adjusted Operating Margin | 32.0% | 33.5% | 31.6% | 32.1% | | Key Adjustments (Q4) | Intangible asset amortization $18.2M, Stock-based compensation $4.7M, Restructuring costs $13.2M, Asset impairment held for sale $84.2M | - | - | - | [Reconciliation of Adjusted Net Earnings and EPS](index=12&type=section&id=Reconciliation%20of%20Adjusted%20Net%20Earnings%20and%20EPS) Q4 FY2025 GAAP pre-tax net earnings were **$(22.9) million**, with adjusted pre-tax net earnings at **$105.1 million** and adjusted diluted EPS at **$0.53**, reflecting similar adjustments to operating margin and the application of a non-GAAP tax rate Reconciliation of Adjusted Net Earnings and EPS | Metric | Q4 FY2025 | Q4 FY2024 | Full Year FY2025 | Full Year FY2024 | | :------------------------- | :----------------- | :----------------- | :------------- | :------------- | | GAAP Pre-Tax Net Earnings | $(22.9) Million USD | $41.7 Million USD | $98.5 Million USD | $185.7 Million USD | | Adjusted Pre-Tax Net Earnings | $105.1 Million USD | $100.8 Million USD | $390.4 Million USD | $365.2 Million USD | | Adjusted Diluted EPS | $0.53 | $0.49 | $1.92 | $1.77 | | Key Adjustments (Q4) | Intangible asset amortization $18.2M, Stock-based compensation $4.7M, Restructuring costs $13.2M, Asset impairment held for sale $84.2M | - | - | - | [Reconciliation of Adjusted Tax Rate](index=12&type=section&id=Reconciliation%20of%20Adjusted%20Tax%20Rate) Q4 FY2025 GAAP effective tax rate was **22.7%**, with an adjusted tax rate of **21.5%**, while full-year GAAP effective tax rate was **25.5%** and adjusted tax rate was **21.5%**, primarily adjusted for discrete items, annual forecast updates, and tax rate impact items like stock-based compensation Reconciliation of Adjusted Tax Rate | Metric | Q4 FY2025 | Q4 FY2024 | Full Year FY2025 | Full Year FY2024 | | :----------------- | :----------------- | :----------------- | :------------- | :------------- | | GAAP Effective Tax Rate | 22.7% | 2.6% | 25.5% | 9.5% | | Adjusted Tax Rate | 21.5% | 22.0% | 21.5% | 22.0% | | Key Adjustments (Q4) | Discrete items +13.9%, Annual forecast update -10.3%, Stock-based compensation -0.9% | - | - | - | [Reconciliation of Adjusted EBITDA](index=14&type=section&id=Reconciliation%20of%20Adjusted%20EBITDA) Q4 FY2025 EBITDA was **$5.8 million**, with adjusted EBITDA at **$115.6 million**, while full-year EBITDA was **$213.0 million** and adjusted EBITDA was **$429.6 million**, with adjustments including depreciation, amortization, stock-based compensation, restructuring costs, and asset impairment held for sale Reconciliation of Adjusted EBITDA | Metric | Q4 FY2025 | Q4 FY2024 | Full Year FY2025 | Full Year FY2024 | | :--------------------------------- | :----------------- | :----------------- | :------------- | :------------- | | EBITDA | $5.8 Million USD | $71.3 Million USD | $213.0 Million USD | $309.8 Million USD | | Adjusted EBITDA | $115.6 Million USD | $111.1 Million USD | $429.6 Million USD | $411.0 Million USD | | Key Adjustments (Q4) | Stock-based compensation $4.7M, Restructuring costs $13.2M, Asset impairment held for sale $84.2M | - | - | - | [Consolidated Financial Statements](index=8&type=section&id=Consolidated%20Financial%20Statements) [Condensed Consolidated Statements of Earnings](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Earnings) Q4 FY2025 net sales were **$317.0 million**, resulting in a net loss of **$17.7 million** and diluted loss per share of **$0.11**, while full-year net sales reached **$1.22 billion** with net earnings of **$73.4 million** and diluted EPS of **$0.46** Condensed Consolidated Statements of Earnings Summary | Metric | Q4 FY2025 | Q4 FY2024 | Full Year FY2025 | Full Year FY2024 | | :------------------- | :----------------- | :----------------- | :------------- | :------------- | | Net Sales | $316,964 Thousand USD | $306,098 Thousand USD | $1,219,635 Thousand USD | $1,159,060 Thousand USD | | Operating Income | $(23,860) Thousand USD | $45,822 Thousand USD | $102,255 Thousand USD | $206,686 Thousand USD | | Net Earnings | $(17,677) Thousand USD | $40,587 Thousand USD | $73,400 Thousand USD | $168,105 Thousand USD | | Diluted EPS | $(0.11) | $0.25 | $0.46 | $1.05 | [Condensed Consolidated Balance Sheets](index=9&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets were **$2.56 billion**, a decrease from **$2.70 billion** in the prior year, with cash and equivalents increasing to **$162.2 million**, total liabilities at **$655.2 million**, and shareholders' equity at **$1.92 billion** Condensed Consolidated Balance Sheets Summary | Metric | June 30, 2025 | June 30, 2024 | | :------------------- | :-------------- | :-------------- | | Cash and Equivalents | $162,186 Thousand USD | $151,791 Thousand USD | | Total Assets | $2,557,868 Thousand USD | $2,703,867 Thousand USD | | Total Liabilities | $655,159 Thousand USD | $638,017 Thousand USD | | Shareholders' Equity | $1,918,808 Thousand USD | $2,068,850 Thousand USD | [Condensed Consolidated Statements of Cash Flows](index=15&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Full-year FY2025 net cash provided by operating activities was **$287.6 million**, net cash used in investing activities was **$35.2 million**, and net cash used in financing activities was **$253.9 million**, resulting in cash and equivalents of **$162.2 million** at period-end Condensed Consolidated Statements of Cash Flows Summary | Metric | Full Year FY2025 | Full Year FY2024 | | :----------------------- | :------------- | :------------- | | Net Cash Provided by Operating Activities | $287,556 Thousand USD | $298,981 Thousand USD | | Net Cash Used in Investing Activities | $(35,183) Thousand USD | $(203,030) Thousand USD | | Net Cash Used in Financing Activities | $(253,905) Thousand USD | $(122,398) Thousand USD | | Cash and Equivalents at Period End | $162,186 Thousand USD | $151,791 Thousand USD | [Company Information & Forward-Looking Statements](index=7&type=section&id=Company%20Information%20%26%20Forward-Looking%20Statements) [Company Overview](index=7&type=section&id=Company%20Overview) Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostics, supporting bioprocess and disease research, drug discovery, and clinical testing - Bio-Techne Corporation is a global life sciences company, offering innovative tools and bioactive reagents for research and clinical diagnostics[31](index=31&type=chunk) Company Key Information | Metric | Data | | :----- | :----- | | FY2025 Net Sales | Approximately $1.2 Billion USD | | Global Employees | Approximately 3,100 | [Forward-Looking Statements](index=7&type=section&id=Forward-Looking%20Statements) This press release contains forward-looking statements subject to risks and uncertainties that could impact actual operating results, including new brand initiatives, business integration, product launches, funding for customer research, price competition, macroeconomic conditions, and currency fluctuations - Forward-looking statements involve risks and uncertainties that could affect actual operating results, including new brand and marketing initiatives, integration of new businesses and leadership, new product launches and acceptance, customer research funding and focus, increased price competition from biotechnology research product manufacturers, macroeconomic conditions, foreign currency fluctuations, and R&D costs and outcomes[29](index=29&type=chunk) - Investors should consult the "Risk Factors" section in the company's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the SEC for additional relevant information[30](index=30&type=chunk)

Core Viewpoint - Bio-Techne Corporation has entered into an agreement for Mdxhealth SA to acquire its Exosome Diagnostics Inc. business, which includes the ExoDx Prostate (EPI) test and a CLIA-certified clinical laboratory, while Bio-Techne retains access to the proprietary exosome-based technology for future kit development [1][2]. Group 1: Transaction Details - Mdxhealth is seen as an ideal acquirer for the ExoDx Prostate test and laboratory, enhancing its leadership in urology and prostate cancer diagnostics [2]. - Bio-Techne will receive $5 million in MDXH stock along with future considerations as part of the transaction, expected to close in the first quarter of Bio-Techne's fiscal 2026 [2]. Group 2: Strategic Implications - The acquisition allows Bio-Techne to focus on developing high-value, high-margin products for life science research and clinical diagnostics, thereby improving its operating margin profile [2]. - Mdxhealth views the ExoDx Prostate test as a strategic fit that will help men make informed decisions regarding prostate biopsies, building on Bio-Techne's success in delivering this information [2]. Group 3: Company Background - Bio-Techne Corporation is a global life sciences company with approximately $1.2 billion in net sales for fiscal 2024 and over 3,000 employees worldwide, providing innovative tools and bioactive reagents for research and clinical diagnostics [6]. - Mdxhealth specializes in precision diagnostics for cancer, utilizing proprietary genetic and molecular technologies to assist in the diagnosis and prognosis of urologic cancers [7].

Core Insights - Sidra Medicine has been awarded a $100,000 G-Rex® Grant to develop a CAR-T cell production platform focused on pediatric oncology [1][2] - The grant will facilitate the preclinical development of a CD19 CAR-T cell therapy product and support the implementation of a fully closed system, semi-automated G-Rex production compliant with current Good Manufacturing Practices (cGMPs) [2][3] - ScaleReady's G-Rex Grant Program has committed over $40 million to advance cell and gene-modified cell therapy (CGT) development and manufacturing [5] Company Developments - Sidra Medicine aims to enhance treatment protocols for pediatric diseases, leveraging the G-Rex® method for efficient T cell manufacturing [3][4] - The G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials [8] - ScaleReady has introduced a new program, LEAN Cell & Gene™, to help CGT entities improve operational efficiency and product quality [6] Industry Context - The G-Rex centric manufacturing process offers significant technical and economic advantages for CAR-T manufacturing in Qatar and the Middle East [4] - The G-Rex Grant recipients gain access to exclusive support from ScaleReady's consortium, enhancing their capabilities in cGMP manufacturing and regulatory affairs [5][9] - Bio-Techne Corporation collaborates with Wilson Wolf to provide tailored products for G-Rex® Bioreactors, supporting high throughput closed-system manufacturing [11]

Core Insights - Bio-Techne Corporation (TECH) is scheduled to release its fourth-quarter fiscal 2025 results on August 6, before market opening [1] - The company reported adjusted earnings per share (EPS) of 56 cents in the last quarter, exceeding the Zacks Consensus Estimate by 9.8%, with an average surprise of 6.74% over the past four quarters [1][3] Q4 Estimates for TECH - The Zacks Consensus Estimate for Bio-Techne's revenues is $317.4 million, reflecting a 3.7% increase from the previous year [2] - The EPS estimate suggests a 2% year-over-year improvement to 50 cents [2] Estimate Revision Trend - Earnings estimates for the fourth quarter have remained stable at 50 cents over the past 60 days [3] Factors Impacting Performance - Management noted macro uncertainties, including tariffs and potential NIH budget cuts, which could temporarily slow growth momentum in Q4 [4] - The Protein Sciences division accounted for 72% of net sales in Q3, with potential modest impacts from the divestment of the fetal bovine serum business [5] Growth Drivers - Bio-Techne is expected to benefit from strong demand for research reagents, protein analysis tools, and cell therapy workflow solutions [6] - The FDA's shift away from animal testing may enhance growth for Bio-Techne's organoid solutions, providing ethical and cost-effective alternatives [7] - The protein analytical instrumentation business, particularly the Maurice platform, is anticipated to show strong momentum [8][9] Segment Performance - The Biologics segment's revenue estimate is $225 million, up 5.1% from the previous year, driven by instrument placements and consumables [9] - The Spatial Biology segment is expected to generate $93 million in revenue, a 2.2% increase year-over-year, despite facing NIH funding uncertainties [12] Earnings ESP and Zacks Rank - Bio-Techne has an Earnings ESP of 0.00%, indicating no expected earnings surprise [13] - The company currently holds a Zacks Rank of 4 (Sell) [13]

Core Insights - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, announced the awarding of $665,000 in G-Rex Grant funding to three investigators at the University of Minnesota's Center for Genome Engineering [1] Funding Details - Dr. Branden Moriarity received a $300,000 G-Rex Grant for a novel hyper-functional CAR NK cell therapy targeting advanced epithelial ovarian cancer in a Phase 1 clinical trial [2] - Dr. Beau Webber was awarded $240,000 for preclinical development of a novel TIL therapy for various solid tumors [3] - Dr. Joseph Skeate received $125,000 to support process development for TPP1 expressing T cells therapy for Batten Disease [4] Industry Impact - The G-Rex Grant Program has surpassed $40 million in no-cost product commitments aimed at advancing cell and gene-modified cell therapy development and manufacturing [7] - ScaleReady's G-Rex manufacturing platform is utilized by over 800 organizations, producing drug products for approximately 50% of CGT clinical trials and five commercially approved CGT drugs [10] Additional Initiatives - ScaleReady introduced a free program called LEAN Cell & Gene™ to help CGT entities improve efficiency and quality in manufacturing [8]

Group 1 - Bio-Techne Corporation is the market leader in high-quality biological reagents used in the life science market [1] - The company specializes in manufacturing high-quality proteins, antibodies, and immunoassays [1] - Long-term growth in cell biology is expected to benefit the company [1]

Core Viewpoint - Bio-Techne Corporation will host a conference call and webcast to review its fourth quarter and fiscal 2025 financial results on August 6, 2025 [1] Group 1: Conference Call Details - The conference call is scheduled for 8:00 a.m. CDT on August 6, 2025 [1] - Dial-in numbers are provided for both domestic (1-800-274-8461) and international callers (1-203-518-9814) [1] - A recorded rebroadcast will be available from 11:00 a.m. CDT on August 6, 2025, until 11:00 p.m. CDT on September 6, 2025 [2] Group 2: Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics [3] - The company generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [3] - Bio-Techne's products support scientific investigations into biological processes and aid in drug discovery and clinical testing [3]